NCT00870883

N-acetylcysteine Plus Deferoxamine for Patients With Hypotension

Prospective, Randomized, Double-blinded, Placebo-controlled Study of N-acetylcysteine Plus Deferoxamine for Patients With Hypotension as Prophylaxis for Acute Renal Failure

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 81 (actual)
• Sponsor: Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Oxidative stress is associated with kidney damage in several different situations, including hypotension. In animal models it has been shown that the combination of n-acetylcysteine plus deferoxamine is superior to its isolate use in the treatment of several diseases. Thus the investigators aimed to determine if the administration of n-acetylcysteine plus deferoxamine could prevent renal failure in critical ill patients who develops hypotension.

Conditions

• Hypotension
• Acute Renal Failure

Interventions

Type	Name	Description
DRUG	N-acetylcysteine and deferoxamine	N-acetylcysteine bolus dose of 50mg/kg/4h, by a manutention of 100mg/kg/day during 2 days and deferoxamine single dose of 1g administered 15mg/kg/h.

Timeline

• Start date: 2009-03-01
• Primary completion: 2015-05-01
• Completion: 2015-05-01
• First posted: 2009-03-27
• Last updated: 2015-05-28

Locations

1 site across 1 country: Brazil